<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672499</url>
  </required_header>
  <id_info>
    <org_study_id>CORT118335-853</org_study_id>
    <secondary_id>2019-004655-36</secondary_id>
    <nct_id>NCT04672499</nct_id>
  </id_info>
  <brief_title>Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants</brief_title>
  <official_title>A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Miricorilant Tablet Formulations Following Single and Multiple Oral Doses in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corcept Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability, and pharmacokinetics (PK) of miricorilant&#xD;
      (CORT118335) tablet formulations following single and multiple oral administration in healthy&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cohort 1 will evaluate safety, tolerability, and PK of single doses of a 150-mg and a new&#xD;
      300-mg tablet formulation of miricorilant. Cohort 1 treatment will be randomized and open&#xD;
      label.&#xD;
&#xD;
      Optional Cohorts 2 and 3 will evaluate single- and repeated-dose administration of&#xD;
      miricorilant using a formulation, dose, and dose-regimen determined after interim evaluation&#xD;
      of PK and safety data from previous cohorts. Cohort 2 and 3 treatments will be randomized,&#xD;
      blinded, and placebo controlled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Actual">September 7, 2020</completion_date>
  <primary_completion_date type="Actual">September 7, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with One or More Adverse Events</measure>
    <time_frame>Up to 7±2 days after the last dose (up to approximately Day 9 for Cohort 1 and up to approximately Day 23 for Cohorts 2 and 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with One or More Serious Adverse Events</measure>
    <time_frame>Up to 7±2 days after the last dose (up to approximately Day 9 for Cohort 1 and up to approximately Day 23 for Cohorts 2 and 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Discontinued from the Study due to an Adverse Event</measure>
    <time_frame>Up to 7±2 days after the last dose (up to approximately Day 9 for Cohort 1 and up to approximately Day 23 for Cohorts 2 and 3)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of Miricorilant: Elapsed Time from Dosing at which the Analyte was First Quantifiable in a Concentration vs Time Profile (tlag)</measure>
    <time_frame>Single-dose regimens: before dosing and at pre-specified time points up to 72 hours after dosing (Day 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of Miricorilant: Maximum Observed Concentration (Cmax)</measure>
    <time_frame>Single-dose regimens: before dosing and at pre-specified time points up to 72 hours after dosing (Day 4); Repeated-dose regimens: before dosing and at pre-specified time points up to 72 hours after final dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of Miricorilant: Time from Dosing at which Cmax was Apparent (Tmax)</measure>
    <time_frame>Single-dose regimens: before dosing and at pre-specified time points up to 72 hours after dosing (Day 4); Repeated-dose regimens: before dosing and at pre-specified time points up to 72 hours after final dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of Miricorilant: Apparent Elimination Half-life (t1/2)</measure>
    <time_frame>Single-dose regimens: before dosing and at pre-specified time points up to 72 hours after dosing (Day 4); Repeated-dose regimens: before dosing and at pre-specified time points up to 72 hours after final dose (Day 17)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of Miricorilant: Area Under the Curve from Time Zero to the Last Measurable Concentration (AUC0-last)</measure>
    <time_frame>Single-dose regimens: before dosing and at pre-specified time points up to 72 hours after dosing (Day 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK of Miricorilant: Area Under the Curve from Time Zero to 24 Hours Postdose (AUC0-24)</measure>
    <time_frame>Repeated-dose regimens: before dosing and at pre-specified time points up to 72 hours after final dose (Day 17)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Miricorilant 900 mg (Regimen A1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of miricorilant 900 mg (3 X 300 mg) after breakfast on Day 1. Cohort 1 treatment will be randomized and open label.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Miricorilant 300 mg (Regimen A2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of miricorilant 300 mg (2 X 150 mg) after breakfast on Day 1. Cohort 1 treatment will be randomized and open label.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Miricorilant (Regimen B1 and B2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of miricorilant 900 mg (6 X 150 mg) after breakfast on Day 1 (Regimen B1). After a minimum 7-day washout, participants will receive miricorilant 900 mg (6 X 150 mg) qd for 14 days (Regimen B2). Day 1 treatment in Regimen B2 will be in the fasted state; the remaining doses will follow breakfast. Cohort 2 treatments will be randomized and blinded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Placebo (Regimen B1 and B2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single oral dose of placebo matching miricorilant 900 mg (6 X 150 mg) after breakfast on Day 1 (Regimen B1). After a minimum 7-day washout, participants will receive placebo matching miricorilant 900 mg (6 X 150 mg) qd for 14 days (Regimen B2). Day 1 treatment in Regimen B2 will be in the fasted state; the remaining doses will follow breakfast. Cohort 2 treatments will be randomized and blinded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Miricorilant (Regimen C1 and C2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two oral doses (morning and evening) of miricorilant 1350 mg (9 X 150 mg) after a meal on Day 1 (Regimen C1). After a minimum 7-day washout, participants will receive miricorilant 750 mg (5 X 150 mg) after breakfast for 14 days and miricorilant 600 mg (4 X 150 mg) in the evening after a meal for 13 days (Regimen C2). Cohort 3 treatments will be randomized and blinded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Placebo (Regimen C1 and C2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive two oral doses (morning and evening) of placebo matching miricorilant 1350 mg (9 X 150 mg) after a meal on Day 1 (Regimen C1). After a minimum 7-day washout, participants will receive placebo matching miricorilant 750 mg (5 X 150 mg) after breakfast for 14 days and placebo matching miricorilant 600 mg (4 X 150 mg) in the evening after a meal for 13 days (Regimen C2). Cohort 3 treatments will be randomized and blinded.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miricorilant 300 mg tablets</intervention_name>
    <description>Miricorilant 300 mg tablets for oral administration</description>
    <arm_group_label>Cohort 1: Miricorilant 900 mg (Regimen A1)</arm_group_label>
    <other_name>CORT118335</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miricorilant 150 mg tablets</intervention_name>
    <description>Miricorilant 150 mg tablets for oral administration</description>
    <arm_group_label>Cohort 1: Miricorilant 300 mg (Regimen A2)</arm_group_label>
    <arm_group_label>Cohort 2: Miricorilant (Regimen B1 and B2)</arm_group_label>
    <arm_group_label>Cohort 3: Miricorilant (Regimen C1 and C2)</arm_group_label>
    <other_name>CORT118335</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 150 mg tablets</intervention_name>
    <description>Placebo to match miricorilant 150 mg tablets for oral administration</description>
    <arm_group_label>Cohort 2: Placebo (Regimen B1 and B2)</arm_group_label>
    <arm_group_label>Cohort 3: Placebo (Regimen C1 and C2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 to 30.0 kg/m^2&#xD;
&#xD;
          -  Must agree to adhere to the contraception requirements&#xD;
&#xD;
          -  Additional criteria apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received any investigational medicinal product in a clinical research study within the&#xD;
             last 90 days&#xD;
&#xD;
          -  Male participants who have pregnant or lactating partners&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          -  Regular alcohol consumption: a confirmed positive alcohol breath test at screening or&#xD;
             admission&#xD;
&#xD;
          -  Current smokers and those who have smoked or used e-cigarettes or nicotine replacement&#xD;
             products within the last 6 months&#xD;
&#xD;
          -  Females of childbearing potential including those who are pregnant or lactating (all&#xD;
             female subjects must have a negative serum pregnancy test at screening and a negative&#xD;
             urine pregnancy test at admission)&#xD;
&#xD;
          -  Clinically significant abnormal clinical chemistry, haematology or urinalysis as&#xD;
             judged by the Investigator&#xD;
&#xD;
          -  Confirmed positive drugs of abuse test result&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) results&#xD;
&#xD;
          -  Active renal and/or hepatic disease&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, endocrine,&#xD;
             metabolic, chronic respiratory, neurological or psychiatric disorder, as judged by the&#xD;
             Investigator&#xD;
&#xD;
          -  Any form of cancer within the last 2 years (exceptions apply)&#xD;
&#xD;
          -  History and/or symptoms of adrenal insufficiency&#xD;
&#xD;
          -  Regularly consumes liquorice or other glycyrrhetic acid derivatives&#xD;
&#xD;
          -  History of clinically significant gastrointestinal disease&#xD;
&#xD;
          -  Currently using glucocorticoids or have a history of systemic glucocorticoid use&#xD;
             within the last 12 months or 3 months for inhaled products&#xD;
&#xD;
          -  Presence or history of clinically significant allergy requiring treatment&#xD;
&#xD;
          -  Donation or loss of greater than 400 mL of blood within the previous 3 months&#xD;
&#xD;
          -  Taking, or have taken, any prescribed, over-the-counter drug (other than up to 4 g per&#xD;
             day paracetamol) or vitamins/herbal remedies within 14 days. Exceptions may apply on a&#xD;
             case by case basis&#xD;
&#xD;
          -  Additional criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharan Sidhu, MBChB, BAO, MRCS, MFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

